The presently disclosed subject matter relates to midbrain dopamine (DA) neurons (mDA), and precursors thereof, derived from human stem cells at least in part by in vitro differentiation. Therefore there is a need for compositions and methods for differentiating neuronal progenitor cells to be used in treating neurodegenerative disorders such as Parkinson's disease. However the results of these studies showed little in vivo capability to restore neuronal function and often resulted in the growth of unwanted tumors in the patients. Research and technological developments relating to directed differentiation of embryonic and somatic stem cells has taken place in the field of diseases of the central nervous system (CNS), such as for Huntington's, Alzheimer's, Parkinson's, and multiple sclerosis. Previously, embryonic and somatic stem cells were used as therapeutics and model systems for neurodegenerative diseases. The presently disclosed subject matter relates to midbrain dopamine (DA) neurons, and precursors thereof, derived from human stem cells, and uses thereof for cell-based treatment of neurological disorders. 1, 2015, priority to each of which is claimed, and the contents of each of which are incorporated by reference in their entireties herein. This application is a Continuation of International Patent Application No.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |